News

Stereotaxis announced a publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism.”

Anthos Therapeutics announces that 1287 patients enrolled across 95 global study sites in the AZALEA-TIMI 71 Ph2 study evaluating the safety and tolerability of abelacimab compared to rivaroxaban.

JACC Focus Seminar aims to address racial and ethnic disparities in health care

Their findings suggest it is the viral vector – in this case, an adenovirus used to shuttle the coronavirus’ genetic material into cells – and the way it binds to platelet factor 4 (PF4) once injected that could be the potential mechanism.

Seasoned electrophysiology sales executive joins the Company to expand the commercial footprint of its signal processing technology for arrhythmia care.

Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD.

Medtronic announced it has completed patient enrollment in its pivotal PULSED AF trial evaluating the PulseSelect™ Pulsed Field Ablation System.

ContraBand technology helps restore the heart’s functionality and may significantly improve patients’ quality of life.

Inomagen Therapeutics is developing a revolutionary gene therapy to improve the treatment of atrial fibrillation, a condition afflicting 37 million people worldwide.

November 30, 2021 — One in five individuals avoided healthcare during lockdown in the COVID-19 pandemic, often for potentially urgent symptoms, according to a new study publishing Nov. 23 in PLOS Medicine by Silvan Licher of Erasmus...